1. Mutations and AML: Sampling, Assays, and Interpreting Results

2. This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

3. WHO Classification of AML 2016 Revision

4. 2017 CAP/ASH Guidelines Initial Workup of Acute Leukemia

5. Examples of Clinically Relevant Gene Mutations

6. 2017 CAP/ASH Cytogenetic and Mutational Analysis Guidelines: Initial Workup

7. FLT3 Mutations in AML

8. 2017 ELN Guidelines Recommended Genetic Analyses

9. c-KIT Mutation Testing for CBF-AML

10. New Drugs for the Treatment of AML

11. 7 + 3/Midostaurin vs 7 + 3/Placebo in ND FLT3-Mutated AML

12. Chemotherapy +/− Midostaurin CALGB 10603/RATIFY Results

13. Enasidenib: IDH2-Mutated R/R AML

14. Daunorubicin/Cytarabine Liposome (CPX-351) vs 7 + 3 in Older ND High-Risk AML

15. Gemtuzumab Ozogamicin

16. Newly Approved Agents: AML 2017

17. Companion Diagnostic Tests

18. IDH2 Testing for Enasidenib Treatment

19. t-AML Establishing the Diagnosis

20. MRCs Establishing the Diagnosis

21. When to Conduct Mutation Analysis

22. NPM1 as Marker of Residual Disease

23. Clonal Hematopoiesis

24. Molecular Genetic Testing Methods

25. Common Pitfalls in Molecular Testing

26. The Impact of Recent Changes in AML

27. Future Directions Spliceosome Mutations

28. Key Takeaways

29. Abbreviations

30. Abbreviations (cont)

31. Abbreviations (cont)